Method of treating cancer by administering EGFR and EGFR/IGFIR binding molecules
US9771411B2 · kind B2 · utility
22Cited by
62References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 20, 2015 |
| Grant date | Sep 26, 2017 |
| Priority date | — |
| Expiry date | Jul 21, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.